Florida Mesothelioma Information | Surviving Mesothelioma

Mesothelioma in Florida

Florida Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Florida

Florida Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Florida Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Florida Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: Immunotoxins have been used as tumor-specific cytotoxic agents by various investigators in academics and industry. One of the major limitations has been their low potency in vivo. Potentiators like monensin have been used with great success in vitro but their lipophillic nature has precluded their use in vivo. Liposomes (with long circulating times) containing monensin are being currently investigated as potentiators of immunotoxins in vitro and in vivo. The main objective of this research is to prepare nanocapsules of a carboxylic ionophore, monensin which can bypass the reticuloendothelial system (to be termed as ‘stealth nanocapsules’). These nanocapsules will be used as potentiators of the anti My9 immunotoxin conjugate (IT) which is presently in Phase III clinical trials. The nanocapsules will be fully characterized for their entrapment efficiency, size, stability and pharmacokinetics profile. Stealth monensin nanocapsules will be incubated with the IT conjugate and different human tumor cell lines to see the in vitro potentiation. All in vitro qualitative and quantitative parameters of monensin nanocapsules will be compared to ‘stealth’ monensin liposomes. Monensin nanocapsules will be further tested for their potentiation of IT in vivo using human tumor xenografts in a i.p/i.v. and i.v./i.v. tumor model (using nude mice) with stealth monensin liposomes as controls. Two different human tumors, H- mesothelioma and HL-60 cells will be used as tumor xenografts. The results emanating from the above studies will allow us to decide what drug delivery system to use, polymer based or lipid based. The completion of the above studies will allow us to choose one formulation for Phase I studies to be used in combination with the IT conjugate as a potentiator.

Tags: Drug Delivery System, Drug Design /synthesis /production, Drug Screening /evaluation, Immunotoxicity, Microcapsule, Monensin, Neoplasm /cancer Chemotherapy, Neoplastic Cell Antineoplastic, Pharmacokinetics Athymic Mouse, Calorimetry, Computer Processing Of Laboratory Data, High Performance Liquid Chromatography, Human Tissue, Laboratory Mouse, Scanning Electron Microscopy, Statistics /biometry, Tissue /cell Culture

  • Followup Grant: 5S06GM008111-260048
  • Followup Grant: 3S06GM008111-26S10048
  • Followup Grant: 5S06GM008111-270048
  • Followup Grant: 3S06GM008111-27S10048
  • Followup Grant: 5S06GM008111-280048

Clinical Trials

Condition: Malignant Mesothelioma

Intervention: Drug: vatalanib

More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma Pancreatic Cancer; Sarcoma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: Pemetrexed; Drug: Gemcitabine
More Information

Condition: Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Sarcoma
Intervention: Drug: L-alanosine
More Information

Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
More Information

Condition: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Condition: Advanced Solid Tumors
Intervention: Drug: OSI-930 and erlotinib
More Information

Hospitals and Cancer Centers

Physicians

Lary A. Robinson, M.D.
H. Lee Moffitt Cancer Center & Research Institute
At The University of South Florida
12902 Magnolia Dr.
Tampa, FL 33612

Owens-Corning Fiberglas Corp. v. Ballard
No. 92,963 , SUPREME COURT OF FLORIDA, August 26, 1999, Decided

Williams v. Am. Optical Corp.
Nos. 4D07-143, 4D07-144, 4D07-145, 4D07-146, 4D07-147, 4D07-148, 4D07-149, 4D07-150, 4D07-151, 4D07-153, 4D07-154, 4D07-405, And 4D07-407., COURT OF APPEAL OF FLORIDA, FOURTH DISTRICT, May 28, 2008, Decided

Fernandez v. Union Carbide Corp.
CASE NO. 3D03-3142 , COURT OF APPEAL OF FLORIDA, THIRD DISTRICT, September 6, 2006, Opinion Filed

Greene v. Csx Transp.
1010357 , SUPREME COURT OF ALABAMA, August 30, 2002, Released

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

Get your free copy of
“Surviving Mesothelioma” Today!